regulatory
confidence high
sentiment positive
materiality 0.65
Longeveron receives FDA clearance for Phase 2 trial of laromestrocel in pediatric dilated cardiomyopathy
Longeveron Inc.
- FDA approved IND for a Phase 2 pivotal registration study of laromestrocel for pediatric DCM.
- Trial initiation anticipated in first half of 2026.
- Nearly 40% of children with DCM require heart transplant or die within 2 years of diagnosis.
- Allogeneic mesenchymal stem cell therapy may address anti-inflammatory and pro-vascular mechanisms.